Physician profile
Nathan Lamborn
NPI 1720494537
$10,097.98
in general payments reported to CMS, 2019-2025
27 companies · $1,846 in 2025
The $1,846 reported for 2025 was more than what 77% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $337 · 2020: $428 · 2021: $1,451 · 2022: $807 · 2023: $2,302 · 2024: $2,927 · 2025: $1,846.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,500 · Travel and Lodging: $2,569 · Education: $1,006.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,500.41 |
| Travel and Lodging | $2,568.78 |
| Education | $1,005.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $3,912.09 | 2020-2024 | Senza |
| Medtronic, INC. | $2,936.07 | 2021-2025 | Synchromedii |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $993.75 | 2019-2025 | Relistor |
| Si-Bone, INC. | $420.40 | 2019-2021 | |
| Boston Scientific Corporation | $414.88 | 2019-2025 | General - Pain Management, Wavewriter Alpha Prime 16 |
| Globus Medical, INC. | $385.01 | 2025 | Senza, Vyrsa V1 |
| Abbvie INC. | $188.49 | 2021-2024 | |
| Collegium Pharmaceutical, INC. | $130.40 | 2022-2025 | Belbuca |
| Acacia Pharma INC | $113.90 | 2021 | |
| Avanos Medical | $77.49 | 2019 | |
| Abbott Laboratories | $47.24 | 2021 | |
| Hikma Pharmaceuticals USA | $46.68 | 2022 | |
| Scilex Pharmaceuticals INC. | $45.82 | 2021-2023 | Ztlido |
| Tersera Therapeutics LLC | $44.91 | 2024 | Prialt |
| Indivior INC. | $42.64 | 2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Valinor Pharma, LLC | $41.99 | 2025 | Movantik |
| Orexo US, INC. | $39.62 | 2019-2020 | |
| Zyla Life Sciences, INC. | $36.14 | 2020 | |
| Amgen INC. | $32.99 | 2022 | |
| Uswm, LLC | $31.30 | 2021 | |
| Biodelivery Sciences International, INC. | $27.15 | 2019-2020 | |
| Grt US Holding, INC. | $19.09 | 2020 | |
| Medtronic USA, INC. | $17.40 | 2019 | |
| Alkermes, INC. | $14.42 | 2021 | |
| Arbor Pharmaceuticals, INC. | $13.84 | 2021 | |
| Stimwave Technologies Incorporated | $12.35 | 2021 | |
| Redhill Biopharma INC. | $11.92 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Lamborn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.